Dr. Jennifer J. Knox, MD, MSc
Claim this profilePrincess Margaret Cancer Centre
Studies Liver Cancer
Studies Hepatocellular Carcinoma
6 reported clinical trials
10 drugs studied
Area of expertise
1Liver Cancer
Stage II
Stage I
Stage IV
2Hepatocellular Carcinoma
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Jennifer J. Knox, MD, MSc is currently running
Durvalumab + Tremelimumab
for Liver Cancer
Hepatocellular Carcinoma (HCC) is the third most common cause of death from cancer world wide and the incidence is rising globally. Despite surgical resection in appropriate patients, many patients recur. The results of the IMbrave150 study have established PD-L1 inhibition in combination with VEGF inhibition as a new standard of care highlighting the role of immune checkpoint inhibition in advanced HCC. In addition, the combination of Tremelimumab and Durvalumab has demonstrated efficacy in advanced HCC; the HIMALAYA trial has now completed accrual in treatment naïve patients with advanced HCC. Furthermore the earlier use of immune checkpoint inhibitors in this disease are being explored with adjuvant combination strategies, including the EMERALD-2 trial (NCT03847428). Neoadjuvant treatment in HCC allows for delivery of treatment pre surgery and may enhance pathological responses and improve outcomes. The delivery of combination CTLA-4 and PD-L1 inhibition has demonstrated efficacy in other tumour types in the neoadjuvant setting where the impact on the tumour microenvironment has also been evaluated. The safety and feasibility of Durvalumab and Tremelimumab in resectable HCC has yet to be established. Hypotheses Pre-operative (pre-op) Durvalumab and Tremelimumab treatment is safe and feasible in pre surgical setting for upfront resectable HCC The combination of Durvalumab and Tremelimumab pre-op will result in changes in immune and molecular characteristics within the tumour microenvironment. Overall Study Design This is a phase II, open-label multi-centre study to assess safety of Durvalumab and Tremelimumab treatment in pre-op setting for upfront resectable HCC, followed by adjuvant Durvalumab. 28 patients are expected to enrol at three sites. Patients will receive pre-op: 1 dose Tremelimumab (300mg) (T300) with Durvalumab (1500mg) at cycle 1 and 1 further cycle of Durvalumab (1500mg) only. Post-surgical resection, adjuvant therapy will consist of Durvalumab Q4W for up to a maximum of 12 months in total or 13 cycles of Durvalumab (11 cycles post op). All participants will be treated until progressive disease or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met. All participants will be followed for survival until the end of study. No dose reductions of Tremelimumab and Durvalumab will be allowed. Statistics The primary objective of this study is to assess safety of pre-op treatment with Durvalumab and Tremelimumab. For safety, with the null proportion of patients who discontinue treatment due to AEs, imAEs or SAE is 30% versus the alternative proportion is 10% or less than 10%, a sample size of 28 provides 80% power to detect the proportion difference with a two-sided alpha level of 0.1. The sample size estimate is based on the two-sided exact test for binomial proportion considering Binomial Enumeration method.
Recruiting1 award Phase 2
Cabozantinib
for Liver Cancer
This trial tests cabozantinib in patients with liver cancer who had a liver transplant but whose cancer has returned. Cabozantinib works by blocking proteins that help cancer cells grow. The goal is to see if this drug can control the disease in these patients.
Recruiting3 awards Phase 215 criteria
More about Jennifer J. Knox, MD, MSc
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Jennifer J. Knox, MD, MSc has experience with
- Cabozantinib
- Modified Folforinox (mFFX)
- Cisplatin
- Gemcitabine
- Selumetinib
- Tremelimumab
Breakdown of trials Jennifer J. Knox, MD, MSc has run
Liver Cancer
Hepatocellular Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer J. Knox, MD, MSc specialize in?
Jennifer J. Knox, MD, MSc focuses on Liver Cancer and Hepatocellular Carcinoma. In particular, much of their work with Liver Cancer has involved Stage II patients, or patients who are Stage I.
Is Jennifer J. Knox, MD, MSc currently recruiting for clinical trials?
Yes, Jennifer J. Knox, MD, MSc is currently recruiting for 2 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Jennifer J. Knox, MD, MSc has studied deeply?
Yes, Jennifer J. Knox, MD, MSc has studied treatments such as Cabozantinib, Modified Folforinox (mFFX), Cisplatin.
What is the best way to schedule an appointment with Jennifer J. Knox, MD, MSc?
Apply for one of the trials that Jennifer J. Knox, MD, MSc is conducting.
What is the office address of Jennifer J. Knox, MD, MSc?
The office of Jennifer J. Knox, MD, MSc is located at: Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9 Canada. This is the address for their practice at the Princess Margaret Cancer Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.